Sepsis and Thrombocytopenia: A Nowadays Problem

Daniel A. Gonzalez 1, Rajeswar Kumar 2, Saba Asif 3, Anoushka Bali 4, Ashujot Kaur Dang 5

1. Medicine, Universidad Catolica Santiago de Guayaquil, Guayaquil, ECU 2. Medicine, Rajah Muthaiah Medical College and Hospital, Chidambaram, IND 3. Internal Medicine, Apollo Hospitals, Hyderabad, IND 4. Research, Acharya Shri Chandar College of Medical Sciences and Hospital, Jammu, IND 5. Research, Government Medical College Patiala, Patiala, IND

Corresponding author: Daniel A. Gonzalez, danielgonmon@gmail.com

Abstract

Sepsis is a life-threatening organ failure produced by a dysregulated host response to infection that involves 15.6% of hospital mortality. The most common signs and symptoms of sepsis are hypotension, tachycardia, fever, and leukocytosis, whether suspected or confirmed. Including a major one, thrombocytopenia is a sign that is an independent predictor of poor outcomes in patients with sepsis, increasing their mortality rate and their length of stay in the intensive care unit (ICU). So far, the ongoing treatment for this problem is securing the airway, treating hypoxemia, and providing vascular access for hydration, antibiotic delivery, and vasopressors, if needed. This article has reviewed the different possible mechanisms found for sepsis-associated thrombocytopenia, going from the most acknowledged one as decreased platelet production to the potential aftermath of sepsis itself as disseminated intravascular coagulation (DIC). This article has also discussed the future treatment for patients suffering from thrombocytopenia and sepsis, going from phase I and II trials as GI antagonists to the well-known drug aspirin as a possible treatment for this problem.

Introduction And Background

Sepsis is described as a life-threatening organ failure produced by a dysregulated host response to infection [1]. In a consensus conference, it was defined as a systemic inflammatory response syndrome (SIRS) that occurred due to an infection in 1991 by the American College of Chest Physicians and the Society of Critical Care Medicine. Then, after the 2016 consensus, SIRS was outdated for the definition of sepsis [1,2]. This pathological state affects nearly 5.9% of hospitalized patients and involves 15.6% of hospital mortality. This would mean that approximately 1.7 million US adults were hospitalized for sepsis and that 270,000 deaths occurred in 2014 [3]. Sepsis was shown to be more prevalent in males than in females (mean annual relative risk: 1.28 (95% confidence interval: 1.24-1.32)) and in non-Whites than in Caucasians (mean annual relative risk: 1.90 (95% confidence interval: 1.81-2.00)) [4]. Most of the risk factors for sepsis are related to a patient’s susceptibility to infection [5], Immunosuppressive disorders such as old and young age, acquired immune deficiency syndrome (AIDS), cancer, immunosuppressive medicines, diabetes, alcohol addiction, indwelling catheters, and other factors that influence skin integrity put patients at risk for infection [6].

The clinical features of sepsis differ considerably based on the initial location of the infection, the causative organism, the pattern of acute organ failure, the patient’s underlying health state, and the time between therapy and onset [7]. Hypotension, tachycardia, tachypnea, fever, and leukocytosis are common symptoms of sepsis, whether suspected or confirmed. Signs of end-organ perfusion such as cold skin, cyanosis, and organ malfunction grow as the severity of the situation intensifies (e.g., oliguria, acute kidney injury, and altered mental status) [8,9]. A widely accepted diagnostic strategy does not exist for the clinical diagnosis of sepsis. To identify sepsis accurately, access to a varied collection of clinical data, a bedside presence, and extensive expertise with septic patients are required [10]. For sepsis patients, treatment priorities include securing the airway, treating hypoxemia, and providing vascular access for hydration and antibiotic delivery. Routine laboratory studies, serum lactate, arterial blood gases, cultures from blood, all indwelling vascular access devices, cultures from easily accessible sites such as sputum and urine, and imaging of suspected sources should all be obtained simultaneously (within 45 minutes). Still, this should not delay the administration of fluids and antibiotics [8,11]. It is critical to focus on the importance of sepsis, its high mortality, and the few resources we have to diagnose and prognosticate it. Thrombocytopenia is a major issue and an independent predictor of worse outcomes in patients with sepsis, with increased risk for increased hemorrhage, renal damage, and length of stay in the intensive care unit (ICU). Although thrombocytopenia in sepsis has not been associated as a mortality marker in numerous articles, its mere presence is a burden on the patient and the clinician managing it. This review article will emphasize the relation between sepsis and thrombocytopenia, resuming the mechanism in which sepsis tends to cause thrombocytopenia and the latest management.
**Review**

**Thrombocytopenia in sepsis: the proposed mechanism**

The research mentioned below highlights the efforts made to identify a pathway that might explain the mechanism of thrombocytopenia in sepsis. Table 1 simplifies the classification of the mechanism.

| Main causes                                                                 |
|-----------------------------------------------------------------------------|
| Decreased production of platelets                                           |
| Interaction between platelet receptors                                      |
| Immune-associated thrombocytopenia                                          |
| Platelet sequestration                                                      |
| Consumptive coagulopathy                                                    |

| Other causes of thrombocytopenia in sepsis                                 |
|----------------------------------------------------------------------------|
| Pseudothrombocytopenia by EDTA                                             |
| Hemodilution                                                               |
| History of liver/spleen disease                                            |
| Hematologic malignancy                                                     |
| Myeloproliferative disease                                                 |

**TABLE 1: Proposed mechanism of thrombocytopenia in sepsis**

EDTA: ethylenediaminetetraacetic acid

**Decreased Production of Platelets**

Firstly, it was assumed that the only mechanism of thrombocytopenia in sepsis was the decreased production of platelets, especially in patients with a critical state of sepsis, which can cause nutritional deficiencies and bone marrow failure, which can then lead to massive pancytopenia [12]. However, Segre et al. found the contrary, as a septic episode can lead to thrombopoiesis, meaning that it can increase platelet production and not the hypothesized [13]. Also, Eissa et al. studied neonatal patients with sepsis and found out that the thrombopoiesis rate is high in this population, but the platelet consumption surpasses platelet production. Therefore, they used the reticulated platelet percentage (RP%) and thrombopoietin (TPO); both markers were increased in septic patients and showed that the platelet production rate was high [14]. Moreover, according to research, significant endotoxemia in sepsis increases pro-inflammatory markers such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1, IL-6, and IL-8, which are known for being thrombopoietic, meaning that it can increase platelet production [13,15]. Concluding this mechanism, Middleton et al. researched the natural history of sepsis and platelets and discovered that there are multiple changes in the expression of transcripts and translations in platelets, with the majority (64%) being upregulated [16].

**Interaction Between Platelet Receptors**

Toll-like receptors (TLRs), whose job is to recognize pathogen-associated molecular patterns (PAMPs) on invading microbes, serve an essential role in triggering innate immunity. Platelets are also involved in innate immunity via platelet-derived TLR4. Findings indicate that platelets express a variety of TLRs, with TLR4 playing a functional role in the control of lipopolysaccharide (LPS)-induced thrombocytopenia and TNF-α production [17,18]. Also, Stark et al. showed that platelet-derived TLR4 is sufficient to cause microvascular thrombosis in endotoxemia, irrespective of systemic TNF-α or IL-1β [19].

Platelet-receptor glycoprotein Ibx (GPIx) and the plasma protein von Willebrand factor (vWF) both limit platelet velocity in areas of vascular injury and are involved in hemostasis and thrombosis [20]. Plummer et al. discovered that several bacteria, including Streptococcus sanguis, have serine-rich protein A (SrpA), which is similarly recognized by GPIb and permits platelet-bacteria binding in a sialic acid-dependent way [21]. Meanwhile, Yin et al. reported that the platelet adhesion receptor GPIb-IX plays an essential role in LPS-induced thrombosis and thrombocytopenia, and they proposed that targeting GPIb as an antiplatelet approach might help manage endotoxemia [22]. Glycoprotein IIB/IIIa (GPIIb/IIIa) is the most prevalent
platelet glycoprotein and plays a vital role in platelet aggregation via fibrinogen bridging. It also collaborates with fibrinogen binding, vWF, fibronectin and vitronectin, and platelet aggregation. Furthermore, Borrelia burgdorferi has been found to bind platelets via these receptors and Staphylococcus aureus via fibrinogen. Platelet-activating factor (PAF) is essential for developing LPS-induced thrombocytopenia and neutropenia in dogs. Tsuchiya et al. employed a canine model and discovered a drop in sepsis-associated thrombocytopenia (SAT) in the PAF antagonist-treated group. However, the platelet-activating factor antagonist had no advantage over the placebo in terms of survival, hemodynamic state, respiratory function, or organ failure ratings in sepsis.

**Immune-Associated Thrombocytopenia**

Hemophagocytosis is an unrestrained proliferation and activation of monocytes and macrophages that aggressively eat hemopoietic cells; it has been suggested to be involved in the development of thrombocytopenia in sepsis. According to Stephan et al., thrombocytopenia in some critically ill patients may be associated with the presence of platelet autoantibodies, as seen in 30% of the patients they evaluated with sepsis. There is also evidence that phagocytosis may be involved in the process of SAT, as the macrophage colony-stimulating factor is overproduced when an infection is present. Furthermore, a recent study used FcRiIA transgenic mice to show that this receptor plays a dominant role in immune complex-mediated thrombocytopenia and platelet sequestration in mouse models of systemic inflammation, including stimulation with immune complexes of IgG and LPS, which are highly relevant to sepsis caused by gram-negative bacteria.

**Platelet Sequestration**

Specific LPS serotypes O8 and O9 rapidly produce platelet sequestration, activation, thrombocytopenia in capillary-rich organs such as the lungs and liver, and increased mortality. Triflavin, an antiplatelet peptide consisting Arg-Gly-Asp isolated from Trimeresurus Aavoviridis venom, can prevent platelet sequestration through many complex mechanisms, especially the one induced in LPS sepsis. Sheu et al. suggested that triflavin either significantly prevented platelet aggregation by acting on fibrinogen and GPIIb/IIIa, resulting in decreased thromboxane A2 production, or hindered platelet adherence to subendothelial matrices, resulting in a reversal of platelet sequestration in the blood and liver of LPS-treated rats. In the end, they reported that triflavin prevented thrombocytopenia in sepsis.

**Consumptive Coagulopathy**

Exaggerated immunological responses in sepsis are frequently associated with excessive and dysregulated activation of coagulation and thrombosis, presenting as disseminated intravascular coagulation (DIC). Microthrombi quickly grow inside small and medium arteries during DIC, causing disrupted tissue oxygenation, multiple organ failure, and circulatory collapse. The combining activation and deactivation of platelets can lead to excessive consumption, resulting in profound thrombocytopenia. Severe infection is the most prevalent cause of an acute, significantly reduced platelet count (e.g., sepsis). Neame et al. claimed that moderate thrombocytopenia could be triggered by sepsis alone, but DIC is commonly the culprit when platelets fall below 50,000/L.

**Other Causes of Thrombocytopenia During Sepsis**

While the mechanisms mentioned above are the most common that can cause thrombocytopenia, a few more can be involved during sepsis. Ethylenediaminetetraacetic acid (EDTA) is frequently used as an anticoagulant in laboratory medicine. Pseudothrombocytopenia occurs during blood sample collection when EDTA-dependent antiplatelet antibodies react with GPIIb/IIIa and produce platelet agglutination and clumping in vitro, resulting in false-negative findings. Hemodilution during massive crystalloid, colloid, or blood product transfusion can lead to thrombocytopenia. Additionally, sepsis with a history of liver/splenic disease, hematologic malignancy, or myeloproliferative condition is frequently accompanied by significant and persistent thrombocytopenia, which is more likely due to the underlying illness than sepsis itself.

**Future treatment prospects**

The mere presence of thrombocytopenia is a factor in adverse prognosis in an ICU patient. At the same time, having sepsis, the patient will have a bleak outlook. Therefore, a lot of new and old drugs focused on improving the overall outcome of patients with sepsis-associated thrombocytopenia by pinpointing the previously mentioned proposed mechanism of thrombocytopenia. Table 2 summarizes the following studies.

IL-11 acts in conjunction with IL-3, thrombopoietin, and megakaryocyte growth and development factor (MGDF) as a potent megakaryocyteopoiesis and thrombopoietic factor. Liu et al. performed a systematic review and meta-analysis that suggests that recombinant human interleukin-11 (rhIL-11), also known in the market as ‘Oprelvekin’ and ‘Neumega,’ is effective and safe in the treatment of chemotherapy-induced thrombocytopenia in patients with acute leukemia. However, one of the main issues is the development of
capillary leak syndrome, which occurs when fluids from the circulatory system seep into tissue outside of the circulation [42,43]. Meanwhile, Wan et al. realized in a case-control study that IL-11 has a protective impact and can hasten platelet recovery while significantly reducing the degree of inflammatory reactions, decreasing mortality in sepsis patients with thrombocytopenia [44].

Platelet-platelet binding through fibrinogen is mediated by GPIIb/IIIa receptor inhibitors; this activation leads to multiple platelets forming a lasting secondary platelet plug. In the market, the commercially available GPIIb/IIIa receptor inhibitors include abciximab, eptifibatide, and tirofiban [45,60]. Sharron et al. proved that GPIIb/IIIa inhibitors (eptifibatide) and other antiplatelet agents led to less severe sepsis and lengthened survival in a murine model of abdominal sepsis. This was found in one of their previous study, in which they reported acute sepsis-induced cytotoxic platelet expression of a granzyme B. Eptifibatide inhibits granzyme B-mediated apoptosis in the spleen and lung, which ends up slowing the progression of sepsis [47]. The "Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial" described that one of the most significant adverse effects of eptifibatide was bleeding. Usually, the bleeding was mild and happened at femoral access sites, leading to increased red cell transfusions compared to placebo [48].

Thrombopoietin is an important hormone that regulates megakaryocyte formation, increasing the number of platelets [49]. Therefore, Wu et al. are now evaluating the safety and effectiveness of recombinant human thrombopoietin (rhTPO) against placebo in severe sepsis patients with thrombocytopenia. The study has an established total of 708 patients with sepsis-associated thrombocytopenia and will undergo recombinant human thrombopoietin or placebo (in a 1:1 ratio). It will have two endpoints: seven-day all-cause mortality and 28-day all-cause mortality [50]. Usually, the main concern in using thrombopoietin is the increase in blood pressure and the risk of thrombosis. However, no severe adverse reaction was reported in the studies that used rhTPO [51,52].

Anfibatide is a GPIbα antagonist that interferes with vWF and thrombin binding, consequently inhibiting the initiation of platelet adhesion and thrombosis [53]. Hou et al. conducted a clinical trial involving 94 healthy human volunteers in phase I clinical trial and showed that it could inhibit 90% of ristocetin platelet aggregation. So far, it has been concluded that anfibatide is a safe and powerful antiplatelet reagent with high promise for future antithrombotic treatment [54]. In the last phase I clinical trial using anfibatide, no serious adverse effect occurred, and no anti-anfibatide antibodies were found in the participants [53,54].

An ongoing double-blind, randomized, placebo-controlled study uses aspirin, a low-cost and widely available treatment, to safely lower sepsis-related fatalities. The overall adverse effect of aspirin is well-known, being any hemorrhagic injury such as gastrointestinal bleeding and gastric or duodenal ulcers [55]. The Aspirin to Inhibit SEPSIS trial (ANTISEPSIS) evaluates 19,000 older Australians and the use of a 100 mg dose of aspirin once daily versus placebo. The study tries to find about three possible outcomes: aspirin reduces the mortality due to sepsis, lowers the admission to ICU for sepsis, and decreases the admission to transfusions compared to placebo [48]. Finding out if aspirin, a low-cost and widely available treatment, is a safe bet in this study with nearly zero limitations [56].

| References | Year | Design | Antiplatelet therapy | Comment |
|------------|------|--------|----------------------|---------|
| Liu et al. [42] | 2020 | Meta-analysis | rhIL-11 | Concluded that rhIL-11 is effective for chemotherapy-induced thrombocytopenia |
| Sharron et al. [47] | 2012 | Experimental trial | GPIIb/IIIa receptor inhibitor eptifibatide | GPIIb/IIIa inhibitors and other antiplatelet agents may be beneficial in sepsis |
| Wu et al. [50] | 2015-ongoing | Randomized, open-label, placebo-controlled | rhTPO | Thrombopoietin for severe sepsis patients with thrombocytopenia |
| Hou et al. [54] | 2013 | Clinical trial | GPIIb antagonist | Anfibatide occupies around 95% of GPIIb while inhibiting up to 90% of ristocetin-specific platelet aggregation |
| Eisen et al. [56] | 2016-ongoing | Double-blinded, randomized, placebo-controlled | Low-dose aspirin | Finding out if aspirin, a low-cost and widely available treatment, lowers sepsis-related fatalities in a safe manner |

**TABLE 2: Characteristics of the included studies**

rhIL-11: recombinant human interleukin-11, GPIIb/IIIa: glycoprotein IIb/IIIa, rhTPO: recombinant human thrombopoietin

**Conclusions**

Any patient with new or ongoing thrombocytopenia is a poor outcome marker in the ICU; summing up,
sepsis can lead to a threatening condition. So far, in every study reviewed, there is no precise proposed mechanism for thrombocytopenia in sepsis, but we are close to reaching one. This review has shared the theorized mechanisms that could be helpful in future targeting of treatment. Although many coming drugs are quite inaccessible, such as IL-11 or antithrombin and GPIIbα antagonist novel drug, hopefully, other available and cheap drugs, such as aspirin, will work in the ANTISEPSIS trial. This work aims to show the relevance of finding a mechanism that genuinely fits sepsis-associated thrombocytopenia and the prospect of a treatment that may reduce this catastrophic disease.

Studies of sepsis and thrombocytopenia have increased exponentially over the last 30 years. Future clinical trials should emphasize the importance of thrombocytopenia in sepsis, understanding the latest pathway of sepsis-associated thrombocytopenia, and the therapeutics that this critical problem needs.

### Additional Information

#### Disclosures

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

#### References

1. Singer M, Deutschman CS, Seymour CW, et al.: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016, 315:801-10. 10.1001/jama.2016.0287
2. Esposito S, De Simone G, Boccia G, De Caro F, Pagliano P.: Sepsis and septic shock: new definitions, new diagnostic and therapeutic approaches. J Glob Antimicrob Resist. 2017, 10:204-12. 10.1016/j.jgar.2017.06.015
3. Rhee C, Danese R, Epstein L, et al.: Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA. 2017, 318:1241-9. 10.1001/jama.2017.13836
4. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003, 348:1546-54. 10.1056/NEJMoa022139
5. Cecconi M, Evans L, Levy M, Rhodes A: Sepsis and septic shock. Lancet. 2018, 392:75-87. 10.1016/S0140-6736(18)30696-2
6. Vincent JL, Salit Y, Sprung CL, et al.: Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006, 34:544-53. 10.1097/01.ccm.0000194725.48928.5a
7. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med. 2015, 369:840-51. 10.1056/NEJMra1400126
8. Evans L, Rhodes A, Alhazzani W, et al.: Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2019. Intensive Care Med. 2020, 47:1181-247. 10.1002/jama.2016.05066-y
9. Levy MM, Fink MP, Marshall JC, et al.: 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003, 31:1250-6. 10.1097/01.CCM.0000080630.02075.9E
10. Taeb AM, Hooper MH, Marik PE: Sepsis: current definition, pathophysiology, diagnosis, and management. Nutr Clin Pract. 2017, 32:296-508. 10.1177/0884533617695243
11. Howell MD, Davis AM: Management of sepsis and septic shock. JAMA. 2017, 317:847-8. 10.1001/jama.2017.0131
12. de Stoppelaar SF, van t Veer C, van der Poll T: The role of platelets in sepsis. Thromb Haemost. 2014, 112:666-77. 10.1160/TH14-01-0126
13. Segre E, Pizzolotti L, Lison D, et al.: May thrombopoietin be a useful marker of sepsis severity assessment in patients with SIRS entering the emergency department?. Clin Chem Lab Med. 2014, 52:1479-83. 10.1515/cclm-2014-0129
14. Eissa DS, El-Farrath RA: New insights into thrombopoiesis in neonatal sepsis. Platelets. 2013, 24:122-8. 10.3109/08845336.2012.696748
15. Schwertz H, Köster S, Kahr WH, et al.: Anucleate platelets generate progeny. Blood. 2010, 115:5801-9. 10.1182/blood-2009-08-259558
16. Middleton EA, Rowley JW, Campbell RA, et al.: Sepsis alters the transcriptional and translational landscape of human and murine platelets. Blood. 2019, 134:911-23. 10.1182/blood.201900067
17. Aslam R, Speck ER, Kim M, et al.: Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood. 2006, 107:637-41. 10.1182/blood-2005-06-2202
18. Cognasse F, Hamze H, Chavarin P, Genin C, Garraud O: Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol. 2005, 83:196-8. 10.1111/j.1440-1711.2005.00714.x
19. Stark RJ, Aghakasiri N, Rumbaut RE: Platelet-derived Toll-like receptor 4 (Tlr-4) is sufficient to promote microvascular thrombosis in endotoxemia. PLoS One. 2012, 7:e41254. 10.1371/journal.pone.0041254
20. Huizinga EG, Tsuij S, Romijn RA, Schiphorst ME, de Groot PG, Sema Jj, Gros P: Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A domain. Science. 2002, 297:1176-9. 10.1126/science.107355
21. Plummer C, Wu H, Kerrigan SW, Meade G, Cox D, Ian Douglas CW: A serine-rich glycoprotein of Streptococcus sanguis mediates adhesion to platelets via GPIb. Br J Haematol. 2005, 129:101-9. 10.1111/j.1365-2141.2005.05421.x
22. Yin H, Stojanovic-Terpo A, Xu W, et al.: Role for platelet glycoprotein Ib-IX and effects of its inhibition in
endotoxemia-induced thrombosis, thrombocytopenia, and mortality. Arterioscler Thromb Vasc Biol. 2015, 35:2529-37. 10.1161/ATVBAHA.115.302359

23. Bennett JS: Structure and function of the platelet integrin alphaIIbbeta3. J Clin Invest. 2005, 115:5363-9. 10.1172/JCI200589

24. Coburn J, Leong IM, Erban JR: Integrin alpha Ibbeta 5 mediates binding of the Lyme disease agent Borrelia burgdorferi to human platelets. Proc Natl Acad Sci U S A. 1995, 90:7059-63. 10.1073/pnas.90.15.7059

25. Siboo IR, Cheung AL, Bayer AS, Sullam PM: Clumping factor A mediates binding of Staphylococcus aureus to human platelets. Infect Immun. 2001, 69:5120-7. 10.1128/IAI.69.5.5120-5127.2001

26. Tsuchiya R, Kyotani K, Scott MA, et al.: Role of platelet activating factor in development of thrombocytopenia and neutropenia in dogs with endotocxemia. Am J Vet Res. 1999, 60:216-21.

27. Vincent JL, Spanos H, Bakker J, Webster NR, Curtis L: Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med. 2000, 28:638-42. 10.1097/00003246-200003000-00006

28. François B, Trimourea F, Vignon P, Fize P, Praloran V, Gastinne H: Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997, 105:114-20. 10.1016/S0002-9440(97)01156-8

29. Stéphan F, Cheffi MA, Kaplan C, Maillet J, Novara A, Fagon J, Bonnet F: Autoantibodies against platelet glycoproteins in critically ill patients with thrombocytopenia. Am J Med. 2000, 108:554-60. 10.1016/S0002-9546(00)00352-6

30. Cloutier N, Allayes I, Marcoux G, et al.: Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proc Natl Acad Sci U S A. 2018, 115:1550-9. 10.1073/pnas.1720531115

31. Zhao L, Ohtaki Y, Yamaguchi K, et al.: LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood. 2002, 100:3235-9. 10.1182/blood-2002-01-0252

32. Huang TF, Sheu JR, Teng CM, Chen SW, Liu CS: Triflavin, an antiplatelet arg-gly-asp-containing peptide, is a specific antagonist of a platelet membrane glycoprotein IIb-IIIa complex. J Biochem. 1991, 109:328-34. 10.1093/oxfordjournals.jbchem.a123581

33. Sheu JR, Hung WC, Wu CH, et al.: Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in rat model of septicemia. Circulation. 1999, 99:3056-62. 10.1161/01.cir.99.23.3056

34. Levi M, Ten Cate H: Disseminated intravascular coagulation. N Engl J Med. 1999, 341:586-92. 10.1056/NEJM199902063360603

35. Neame PB, Kelton JG, Walker IR, Stewart IO, Nosell HL, Hirsh J: Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood. 1980, 56:88-92. 10.1182/blood.v56.i.88.88

36. Lippi G, Plebani M: EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. Clin Chem Lab Med. 2012, 50:1281-5. 10.1515/cclm-2012-0081

37. Singbartl K, Singbartl G, Schleiner W: Hemodialysis induced thrombocytopenia. Anesth Analg. 1999, 88:1006. 10.1097/00000539-199902001-00100

38. Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H: Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol. 2014, 20:2395-605. 10.3748/wjg.v20.i10.2395

39. Stasi R: How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2012, 2012:191-7. 10.1182/asheducation-2012.1.191

40. Zarychanski R, Houston DS: Assessing thrombocytopenia in the intensive care unit: the past, present, and future. Hematology Am Soc Hematol Educ Program. 2017, 2017:560-6. 10.1182/ashc17-2017.1.660

41. Du X, Williams DA: Interleukin-11: review of molecular, cell biology, and clinical use . Blood. 1997, 89:5897-908. 10.1182/blood.V89.11.5897

42. Liu Z, Wang Y, Yan J, Liu J, Chen B, Zhang L, Cheng L: Efficacy and safety of recombinant human interleukin-11 in the treatment of acute leukaemia patients with chemotherapy-induced thrombocytopenia: a systematic review and meta-analysis. J Eval Clin Pract. 2020, 26:262-71. 10.1111/jep.15152

43. Izzedine H, Mathias A, Amoura Z, Ng JH, Jiaveri KD: Anticancer drug-induced capillary leak syndrome. Kidney Int Rep. 2022, 7:945-53. 10.1016/j.ekir.2022.02.014

44. Wan B, Zhang H, Fu H, et al.: Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: a case-control study. Cytokine. 2015, 76:138-43. 10.1016/j.cyto.2015.08.003

45. Sangkhunj K, Shuldrin AR, Klein TE, Altman RB: Platelet aggregation pathway. Pharmacogenet Genomics. 2011, 21:516-21. 10.1097/PPG.0b013e3283463235

46. Schmitt-Sody M, Metz P, Gottschalk O, et al.: Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Inflamm Res. 2007, 56:414-20. 10.1007/s00011-007-0724-3

47. Sharron M, Hopst C, Wilson A, et al.: Platelets induce apoptosis during sepsis in a contact-dependent manner that is inhibited by GPIIb/IIIa blockade. Proc Natl Acad Sci U S A. 2012, 109:21454-6. 10.1073/pnas.1204549

48. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with epitifibatide in patients with acute coronary syndromes. N Engl J Med. 1998, 339:3456-43. 10.1056/NEJM199801153390704

49. Fanucchi M, Glaspay J, Crawford J, et al.: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997, 336:404-9. 10.1056/NEJM199702063360603

50. Wu Q, Ren J, Wang G, et al.: Evaluating the safety and efficacy of recombinant human thrombopoietin among severe sepsis patients with thrombocytopenia: study protocol for a randomized controlled trial. Trials. 2015, 16:220. 10.1186/s13063-015-0746-6

51. Zhou Z, Feng T, Xie Y, et al.: The effect of recombinant human thrombopoietin (rTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial). BMC Infect Dis. 2019, 19:780. 10.1186/s12879-019-4388-2

2022 Gonzalez et al. Cureus 14(5): e25421. DOI 10.7759/cureus.25421
52. Mahévas M, Gerfaud-Valentin M, Moulis G, et al.: Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016, 128:1625-30. 10.1182/blood-2016-03-704734

53. Li BX, Dai X, Xu XR, et al.: In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα. Sci Rep. 2021, 11:11663. 10.1038/s41598-021-91165-8

54. Hou Y, Lei X, Li BX, et al.: The first in vitro and in vivo assessment of anfibatide, a novel glycoprotein Ib antagonist, in mice and in a phase I human clinical trial. Blood. 2013, 122:577. 10.1182/blood.V122.21.577.577

55. Kwok CS, Loke YK: Critical overview on the benefits and harms of aspirin. Pharmaceuticals (Basel). 2010, 3:1491-506. 10.3390/ph3051491

56. Eisen DP, Moore EM, Leder K, et al.: Aspirin To Inhibit SEPSIS (ANTI SEPSIS) randomised controlled trial protocol. BMJ Open. 2017, 7:e013636. 10.1136/bmjopen-2016-013636